Zai Lab Ltd (9688)

Hong Kong
Currency in HKD
21.55
-0.10(-0.46%)
Closed
9688 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
21.2521.90
52 wk Range
10.5625.80
Key Statistics
Edit
Bid/Ask
21.65 / 21.60
Prev. Close
21.65
Open
21.6
Day's Range
21.25-21.9
52 wk Range
10.56-25.8
Volume
1.49M
Average Volume (3m)
2.55M
1-Year Change
42.81%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9688 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
35.92
Upside
+66.68%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Employees
2175
Market
Hong Kong

Compare 9688 to Peers and Sector

Metrics to compare
9688
Peers
Sector
Relationship
P/E Ratio
−11.1x−1.6x−0.6x
PEG Ratio
−1.00−0.020.00
Price/Book
4.5x0.5x2.6x
Price / LTM Sales
8.4x24.1x3.1x
Upside (Analyst Target)
64.4%387.7%48.2%
Fair Value Upside
Unlock18.1%8.0%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.92
(+66.68% Upside)

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
-0.0311 / -0.6185
Revenue / Forecast
795.51M / 789.91M
EPS Revisions
Last 90 days

FAQ

What Is the Zai Lab (9688) Stock Price Today?

The Zai Lab stock price today is 21.55.

What Stock Exchange Does Zai Lab Trade On?

Zai Lab is listed and trades on the Hong Kong stock exchange.

What Is the Stock Symbol for Zai Lab?

The stock symbol for Zai Lab is "9688."

What Is the Zai Lab Market Cap?

As of today, Zai Lab market cap is 23.36B.

What is Zai Lab Earnings Per Share?

The Zai Lab EPS is -2.78.

What Is the Next Zai Lab Earnings Date?

Zai Lab will release its next earnings report on 26 Feb 2025.

From a Technical Analysis Perspective, Is 9688 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.